Use the current FDA label and a gene-therapy center. As of the 2025 label revision, U.S. use is limited to ambulatory patients age 4+ with a confirmed DMD mutation and includes a boxed warning for serious liver injury/acute liver failure.
What this means in real life
Elevidys (delandistrogene moxeparvovec-rokl) is a one-time AAV gene therapy intended to deliver a micro-dystrophin gene. The current U.S. FDA indication is limited to ambulatory people with DMD age 4 years and older who have a confirmed DMD mutation. The label includes a boxed warning for acute serious liver injury and acute liver failure, and product-specific contraindications and precautions must be checked directly.
Eligibility is more than age and diagnosis. A gene-therapy center reviews walking status, exact mutation, antibody testing, liver and cardiac status, infections, vaccinations, medicines and ability to follow an intensive corticosteroid and laboratory-monitoring plan. Prior AAV exposure may affect future trial options, and redosing is not currently routine. Families should understand evidence for micro-dystrophin expression and clinical outcomes separately.
The decision should include near-term infusion and immune risks, uncertain individual benefit, long-term follow-up, travel burden and alternatives. Illness around infusion, abnormal liver tests, jaundice, dark urine, vomiting, abdominal pain or unusual fatigue requires immediate contact with the gene-therapy team according to its plan.
A practical checklist
- ✓
Use the current FDA label—not an older news article—to check indication and contraindications.
- ✓
Complete gene-therapy-center screening for mutation, ambulation, antibodies, liver, heart and infection status.
- ✓
Review the full immune-suppression, vaccination, lab and emergency schedule.
- ✓
Ask how treatment changes future trial or gene-therapy eligibility.
- ✓
Plan travel, caregiver availability and rapid access to the center during the monitoring period.
Questions to bring with you
Use these at the clinic, school meeting, equipment evaluation, program interview or benefits call. Write down the answers and who owns the next step.
- Does this person meet every current label and center criterion?
- What clinical benefit is supported, and where is uncertainty greatest?
- What are the liver, immune, cardiac and other serious risks?
- What symptoms and lab values trigger urgent treatment or hospitalization?
- What alternatives exist now, and what future options could be affected?
Important safety note
This topic can involve serious or immediate risk. Do not start, stop or change treatment from an online answer. Contact the Duchenne care team; use emergency services for urgent symptoms or danger.
Sources used for this guide
Direct links are included so families can check the original guidance and bring it to qualified professionals.
Content review: July 18, 2026. Medical labels, trials, benefits and programs can change after publication.
Did this article answer the question?
A thumbs-down sends the article to the private administrator dashboard for review.